Fish or shellfish consumption could help patients with AMD

Article

A recent study has revealed that higher consumption of fish or shellfish could help to protect eyes against advanced age-related macular degeneration (AMD).

A recent study has revealed that higher consumption of fish or shellfish could help to protect eyes against advanced age-related macular degeneration (AMD). The data has been published in a recent issue of Ophthalmology.

The research, led by Dr Bonnielin K. Swenor from the Wilmer Eye Institute, Johns Hopkins University, Maryland, USA, explored the relationship between fish and shellfish consumption and AMD status in eyes of participants from the Salisbury Eye Evaluation (SEE) Study.

To estimate the level of weekly fish/shellfish consumption, each patient filled out a food frequency questionnaire. The AMD status was determined from fundus photographs obtained at baseline and graded by 2 masked readers for drusen size, retinal pigment epithelium abnormalities, geographic atrophy (GA) and choroidal neovascularization (CNV). The researchers investigated the association between weekly fish/shellfish consumption and the risk of AMD using logistic regression but adjusted for risk factors and correlation between eyes.

The results demonstrated that there was no difference in the distribution of weekly fish/shellfish consumption between specific AMD categories in comparison with controls. In patients with advanced AMD there was less likelihood of them consuming fish/shellfish that were high in omega-3 fatty acids. Additionally, no relationship was found of AMD with the intake of crab and oysters combined, each of which has high levels of zinc.

From the results the researchers concluded that a protective effect of fish/shellfish intake against advanced AMD was supported.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.